PICC Capital
人保资本
PICC Capital (人保资本) appears in elsewhere's corpus only as a deal participant, not as a profiled subject — so there's no grounded description here of its size, structure, or strategy. What the record shows: in April 2022, PICC Capital co-led two consecutive funding rounds in METiS Pharmaceuticals totaling $150 million alongside China Life Private Equity, with Sequoia China, 5Y Capital, CMB International, Lightspeed China, and Source Code Capital among the followers . More recently, per a September 2026 Gaorong Ventures report, it joined a broad syndicate — including Cowin Capital, CASSTAR, Tongcheng Travel, CP Group, and CCB Equity — investing in Xi Wang . Both appearances are in healthcare-adjacent deals, but beyond that, elsewhere's corpus does not cover PICC Capital itself in enough depth for a fuller profile.
AI-generated — may contain errors, please verify.
Coverage
Gaorong Ventures Report: Physical AI, Domestic Computing Power, Controllable Nuclear Fusion, and Medical Innovation Companies Close Major Funding Rounds
From the continuous leap in model capabilities to hard tech crossing the thresholds of engineering and industrialization, a new wave of technological innovation is accelerating toward the real world.
New Tracks, Interdisciplinary Fields, Down-Market Expansion, Data Infrastructure... Four Companies Raise Nearly 1.2 Billion RMB in Funding | FreeS Family Funding News · Vol 10
Looking forward to working alongside more outstanding founders.
5Y News | METiS Pharmaceuticals Closes Two Consecutive Rounds Raising $150 Million Total
Become an industry innovation leader.
Code Engraved | METiS Pharmaceuticals Announces Two Consecutive Rounds totaling $150 Million
The most advanced pipeline programs are expected to begin pivotal clinical trials in 2023.
